BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 32550913)

  • 21. Pyruvate dehydrogenase kinase 1 contributes to cisplatin resistance of ovarian cancer through EGFR activation.
    Zhang M; Cong Q; Zhang XY; Zhang MX; Lu YY; Xu CJ
    J Cell Physiol; 2019 May; 234(5):6361-6370. PubMed ID: 30229902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The SP1-12LOX axis promotes chemoresistance and metastasis of ovarian cancer.
    Zhang Q; Yan G; Lei J; Chen Y; Wang T; Gong J; Zhou Y; Zhao H; Chen H; Zhou Y; Wu L; Zhang J; Zhang X; Wang J; Li Y
    Mol Med; 2020 May; 26(1):39. PubMed ID: 32375633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
    McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
    BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer.
    Han Z; Hong Z; Gao Q; Chen C; Hao Z; Ji T; Hu W; Yan Y; Feng J; Liao S; Wu P; Wang D; Wang S; Zhou J; Ma D
    Hum Gene Ther; 2012 Jan; 23(1):32-45. PubMed ID: 21875334
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MCT1 promotes the cisplatin-resistance by antagonizing Fas in epithelial ovarian cancer.
    Yan C; Yang F; Zhou C; Chen X; Han X; Liu X; Ma H; Zheng W
    Int J Clin Exp Pathol; 2015; 8(3):2710-8. PubMed ID: 26045776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Leukotriene B4 receptor-2 contributes to chemoresistance of SK-OV-3 ovarian cancer cells through activation of signal transducer and activator of transcription-3-linked cascade.
    Park J; Park SY; Kim JH
    Biochim Biophys Acta; 2016 Feb; 1863(2):236-43. PubMed ID: 26597704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. WD repeat domain 5 promotes chemoresistance and Programmed Death-Ligand 1 expression in prostate cancer.
    Zhou Q; Chen X; He H; Peng S; Zhang Y; Zhang J; Cheng L; Liu S; Huang M; Xie R; Lin T; Huang J
    Theranostics; 2021; 11(10):4809-4824. PubMed ID: 33754029
    [No Abstract]   [Full Text] [Related]  

  • 28. Antiparasitic mebendazole (MBZ) effectively overcomes cisplatin resistance in human ovarian cancer cells by inhibiting multiple cancer-associated signaling pathways.
    Huang L; Zhao L; Zhang J; He F; Wang H; Liu Q; Shi D; Ni N; Wagstaff W; Chen C; Reid RR; Haydon RC; Luu HH; Shen L; He TC; Tang L
    Aging (Albany NY); 2021 Jul; 13(13):17407-17427. PubMed ID: 34232919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B.
    Xiao F; Li Y; Wan Y; Xue M
    Cancer Chemother Pharmacol; 2018 May; 81(5):935-947. PubMed ID: 29594361
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Forkhead Box Protein C2 Promotes Epithelial-Mesenchymal Transition, Migration and Invasion in Cisplatin-Resistant Human Ovarian Cancer Cell Line (SKOV3/CDDP).
    Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
    Cell Physiol Biochem; 2016; 39(3):1098-110. PubMed ID: 27562816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MiR-338-3p Enhances Ovarian Cancer Cell Sensitivity to Cisplatin by Downregulating WNT2B.
    Niu Q; Liu Z; Gao J; Wang Q
    Yonsei Med J; 2019 Dec; 60(12):1146-1156. PubMed ID: 31769245
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1.
    Xu S; Fu GB; Tao Z; OuYang J; Kong F; Jiang BH; Wan X; Chen K
    Oncotarget; 2015 Sep; 6(28):26457-71. PubMed ID: 26238185
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Knockdown of MALAT1 enhances chemosensitivity of ovarian cancer cells to cisplatin through inhibiting the Notch1 signaling pathway.
    Bai L; Wang A; Zhang Y; Xu X; Zhang X
    Exp Cell Res; 2018 May; 366(2):161-171. PubMed ID: 29548748
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FOXM1 promotes reprogramming of glucose metabolism in epithelial ovarian cancer cells via activation of GLUT1 and HK2 transcription.
    Wang Y; Yun Y; Wu B; Wen L; Wen M; Yang H; Zhao L; Liu W; Huang S; Wen N; Li Y
    Oncotarget; 2016 Jul; 7(30):47985-47997. PubMed ID: 27351131
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1α-mediated regulation of apoptosis and autophagy.
    Zhang X; Qi Z; Yin H; Yang G
    Theranostics; 2019; 9(4):1096-1114. PubMed ID: 30867818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer-associated mesothelial cells promote ovarian cancer chemoresistance through paracrine osteopontin signaling.
    Qian J; LeSavage BL; Hubka KM; Ma C; Natarajan S; Eggold JT; Xiao Y; Fuh KC; Krishnan V; Enejder A; Heilshorn SC; Dorigo O; Rankin EB
    J Clin Invest; 2021 Aug; 131(16):. PubMed ID: 34396988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ISG15 is downregulated by KLF12 and implicated in maintenance of cancer stem cell-like features in cisplatin-resistant ovarian cancer.
    Zhang Q; Wang J; Qiao H; Huyan L; Liu B; Li C; Jiang J; Zhao F; Wang H; Yan J
    J Cell Mol Med; 2021 May; 25(9):4395-4407. PubMed ID: 33797839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
    Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
    Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BRCA1-IRIS overexpression promotes cisplatin resistance in ovarian cancer cells.
    Chock KL; Allison JM; Shimizu Y; ElShamy WM
    Cancer Res; 2010 Nov; 70(21):8782-91. PubMed ID: 20940403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Snail/FOXK1/Cyr61 Signaling Axis Regulates the Epithelial-Mesenchymal Transition and Metastasis in Colorectal Cancer.
    Huang X; Xiang L; Li Y; Zhao Y; Zhu H; Xiao Y; Liu M; Wu X; Wang Z; Jiang P; Qing H; Zhang Q; Liu G; Zhang W; Li A; Chen Y; Liu S; Wang J
    Cell Physiol Biochem; 2018; 47(2):590-603. PubMed ID: 29794466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.